期刊文献+

系统性红斑狼疮患者外周血白细胞介素9及CD4+白细胞介素9+T细胞的变化及其意义 被引量:14

Abnormality and significance of interleukin-9 and CD4 interleukin-9 T-cells in peripheral blood of patients with systemic lupus erythematosus
原文传递
导出
摘要 目的研究系统性红斑狼疮(SLE)患者外周血中自细胞介素(IL)9mRNA、IL-9蛋白水平以及CD4+IL-9+T细胞百分比及其与临床指标的相关性,并观察糖皮质激素治疗对血浆IL-9水平及外周血CD4+IL-9+T细胞百分比的影响。方法采用实时荧光定量聚合酶链反应(real—timePCR)、酶联免疫吸附试验(ELISA)及流式细胞学分别检测28例SLE患者及12名健康体检者外周血中IL-9mRNA、IL-9蛋白水平及CIM+IL-9+T细胞百分比,比较其在各组中的差异并分析糖皮质激素治疗对其的影响。结果(1)SLE患者外周血IL-9mRNA的表达明显高于健康对照组(P〈0.01);SLE活动组患者血浆IL-9水平及缓解组血浆IL-9水平均明显高于健康对照组[(68±11)ng/L、(56±14)ng/L比(26±6)ng/L,P〈0.01及P〈0.05];SLE活动组患者外周血中CD4+IL-9+T细胞百分比明显高于健康对照组和缓解组(1.96%±0.31%比0.28%±0.05%、0.89%±0.13%,均P〈0,01),缓解组亦高于健康对照组(P〈0.05);(2)血浆IL-9水平和外周血CD4+IL-9+T细胞百分比均与SLE活动性指数(SLEDAI)呈正相关;(3)初发活动期SLE患者在接受甲泼尼龙(0.8nag·kg~·d“)治疗后第1、2、3周血浆IL-9水平及外周血CD4+IL-9+T细胞百分比均低于治疗前。结论IL-9及CD4+IL-9+T细胞可能在SLE的发病中起着重要作用,其含量异常可反映SLE的活动性及严重程度。 Objective To examine the protein and mRNA levels of interleukin-9 (IL-9) and the frequencies of CD4 + IL-9 + T-cells in peripheral blood of patients with systemic lupus erytbematosus ( SLE ) and explore the roles of double positive T cells and IL-9 in the pathogenesis of SLE and the effects of glucocorticoid. Methods Twenty-eight hospitalized SLE patients were recruited and 12 healthy volunteers selected as normal controls. The mRNA levels of IL-9 in peripheral blood were measured by real timepolymerase chain reaction (RT-PCR), plasma protein of IL-9 by enzyme-linked immunosorbent assay (ELISA) and frequencies of CD4 + IL-9 + T-cells by flow cytometry. And the differences between two groups and the effects of glucocortieoid were analyzed. Results ( 1 ) The mRNA levels of IL-9 were significantly elevated in SLE patients as compared with normal controls ( P 〈 0. 01 ). The serum levels of IL-9 were significantly higher in active and inactive SLE patients than those in healthy individuals ( 68 + 11 vs 26 + 6 ng/L, P 〈 0.01 ; 56 s 14 vs 26 s 6 ng/L, P 〈 0.05 ). The percentages of CD4 IL-9 + T-cells increased in active SLE patients (1.96% s0.31% ) versus inactive SLE patients (0.89% s0.13%, P 〈0.01 ) and healthy controls (0.28% s0.05%, P 〈 0. 001 ). And it was higher in inactive SLE patients than that in controls ( P 〈 0.05 ). ( 2 ) The serum levels of IL-9 and the frequencies of CIM + IL-9 T-cells were positively correlated with SLE disease activity index (SLEDAI). ( 3 ) The frequencies of CD4 + IL-9 + T-cells and the serum levels of IL-9 in 8 untreated active SLE patients decreased at weeks 1, 2 and 3 after the therapy of methylprednisolone (0.8 mg . kg-l . d-l) versus those at pre-treatment. Conclusion The abnormalities of IL-9 and CD4 IL-9 T-cells may play an important role in the pathogenesis of SLE. And thefrequencies of CIM IL-9 T-cells and the levels of IL-9 are evaluative parameters of SLE activity and severity.
出处 《中华医学杂志》 CAS CSCD 北大核心 2013年第2期99-103,共5页 National Medical Journal of China
基金 国家自然科学基金(81200507)
关键词 红斑狼疮 系统性 白细胞介素9 糖皮质激素 Lupus erythematosus, systemic Interleukin-9 Glucocorticoid
  • 相关文献

参考文献21

  • 1Foster MH, Kelley VR. Lupus nephritis: update on pathogenesis and disease mechanisms. Semin Nephrol, 1999, 1,9 : 173-181.
  • 2Gee K, Guzzo C, Che Mat NF, et al. The IL-12 family ofcytolines in infection, inflammation-nand autoimmune disorder. Inflamm Allergy Drug Targets, 2009, 8:40-52.
  • 3Lourengo EV, La Cava A. Cytokines in systemic lupus erythematosus. Curt Mol Med, 2009, 9:242-254.
  • 4SG Pasoto, EF Borba, E Bonfa, et al. Lupus pleuritis: a relevant risk factor for pulmonary tuberculosis. Lupus, 2010, 19 : 1585- 1590.
  • 5Bombardier C, Gladman DD, Urowitz MB, et al. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum, 1992, 35:630-640.
  • 6Monteyne P, Renauld JC, Van Broeck J, et al. IL-4-independent regulation of in vivo IL-9 expression. J Immunol, 1997, 159: 2616-2623.
  • 7Knoops L, Renauld JC. IL-9 and its receptor: from signal transduction to tumorigenesis. Growth Factors, 2004, 22 : 207- 215.
  • 8Holbrook ST, Ohls RK, Schibler KR, et al. Effect of interleukin- 9 on clonogenic maturation and cell-cycle status of fetal and adult hematopoietic progenitors. Blood, 1991, 77:2129-2134.
  • 9Liu Y, Teige I, Birnir B, et al. Neuron-mediated generation of regulatory T cells from encephalitogenic T cells suppresses EAE. Natl Med, 2006, 12:518-525.
  • 10Sugimoto T, Ishikawa Y, Yoshimoto T, et al. Interleukin 18 acts on memory T helper cells type 1 to induce airway inflammation and hyperresponsiveness in a naive host mouse. J Exp Med, 2004, 199:535-545.

二级参考文献9

  • 1Wong CK,Lit LC,Tam LS,et al.Hyperproduction of IL-23 and IL17 in patients with systenmic lupus erythematosus:implications for Th17-mediated inflammation in auto-immunity.Clin Immunol,2008,127:385-393.
  • 2Manel N,Unutmaz D,Littman DR.The differentiation of human T (H)-17 cells requires transforming growth factor-beta and induction of nuclear receptor ROR gammat.Nat Immunol,2008,9:641-649.
  • 3Kurasawa K,Hirose K,Sano H,et al.Increased interleukin-17production in patients with systemic sclerosis.Arthritis Rheum,2000,43:2455-2463.
  • 4Suarez A,Lopez P,Gomez J,et al.Enrichment of CD4 +CD25high T cell population in patients with systemic lupus erythematosus treated with glucocorticoids. Ann Rheum Dis,2006,65:1512-1517.
  • 5Bettelli E,Carrier Y,Gao W,et al.Reciprocal developmental pathways for the generation of pathogenic effector Thl7 and regulatory T cells.Nature,2006,441:235-238.
  • 6Hochberg MC.Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.Arthritis Rheum,1997,40:1725.
  • 7Bombardier C,Gladam DD,Urowitzm B,et al.Derivation of the SLEDAI a disease activity index for lupus patients,the committee on prognosis studies in SLE.Arthritis Rheum,1992,35:630-640.
  • 8Langrish CL,Chen Y,Blumenschein WM,et al.IL-23 drives a pathogenic T cell population that induces autoimmune inflammation.J Exp Med,2005,201:233-240.
  • 9Nakae S,Nambu A,Sudo K,et al. Suppression of immune induction of collagen-induced arthritis in IL-17 deficient mice.J Immunol,2003.171:6173-M77.

共引文献17

同被引文献58

引证文献14

二级引证文献41

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部